公开(公告)号：US10858356B2

公开(公告)日：2020-12-08

申请号：US15759872

申请日：2017-09-26

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Hitoshi Yoshino ,  Satoshi Tsuchiya ,  Atsushi Matsuo ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Kyoko Oguri ,  Hiroko Ogawa ,  Yoshikazu Nishimura ,  Yoshiyuki Furuta ,  Hirotaka Kashiwagi ,  Nobuyuki Hori ,  Takuma Kamon ,  Takuya Shiraishi ,  Shoshin Yoshida ,  Takahiro Kawai ,  Satoshi Tanida ,  Masahide Aoki

IPC分类号： A61K31/437 ,  A61P3/04 ,  C07D471/04 ,  C07D519/00 ,  A61P3/10 ,  A61P1/16 ,  A61K31/506 ,  A61K31/4725 ,  A61P3/06 ,  A61K31/444 ,  A61K31/496 ,  A61P9/10 ,  A61K31/5386 ,  A61K31/5377 ,  A61P25/16 ,  A61P25/28 ,  A61K31/4709

摘要： The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.

公开(公告)号：US11814381B2

公开(公告)日：2023-11-14

申请号：US17065122

申请日：2020-10-07

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Hitoshi Yoshino ,  Satoshi Tsuchiya ,  Atsushi Matsuo ,  Tsutomu Sato ,  Masahiro Nishimoto ,  Kyoko Oguri ,  Hiroko Ogawa ,  Yoshikazu Nishimura ,  Yoshiyuki Furuta ,  Hirotaka Kashiwagi ,  Nobuyuki Hori ,  Takuma Kamon ,  Takuya Shiraishi ,  Shoshin Yoshida ,  Takahiro Kawai ,  Satoshi Tanida ,  Masahide Aoki

IPC分类号： A61K31/437 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  A61P25/16 ,  A61P25/28 ,  C07D471/04 ,  A61K31/506 ,  C07D519/00 ,  A61K31/4725 ,  A61K31/444 ,  A61K31/496 ,  A61K31/5386 ,  A61K31/5377 ,  A61K31/4709

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61P1/16 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  A61P25/16 ,  A61P25/28 ,  C07D519/00

摘要： The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.